EA200100300A1 - DRY POWDER CONTAINING EXISTING SUBSTANCE, AND METHOD OF DELIVERY TO LIGHT PATIENT OF EXISTING SUBSTANCE - Google Patents

DRY POWDER CONTAINING EXISTING SUBSTANCE, AND METHOD OF DELIVERY TO LIGHT PATIENT OF EXISTING SUBSTANCE

Info

Publication number
EA200100300A1
EA200100300A1 EA200100300A EA200100300A EA200100300A1 EA 200100300 A1 EA200100300 A1 EA 200100300A1 EA 200100300 A EA200100300 A EA 200100300A EA 200100300 A EA200100300 A EA 200100300A EA 200100300 A1 EA200100300 A1 EA 200100300A1
Authority
EA
Eurasian Patent Office
Prior art keywords
existing substance
dry powder
delivery
powder containing
patient
Prior art date
Application number
EA200100300A
Other languages
Russian (ru)
Other versions
EA003476B1 (en
Inventor
Эндрю Кларк
Мэй-Чанг Куо
Сисили Лалор
Берри Джон Алдус
Original Assignee
Инхэл Терапьютик Системз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инхэл Терапьютик Системз, Инк. filed Critical Инхэл Терапьютик Системз, Инк.
Publication of EA200100300A1 publication Critical patent/EA200100300A1/en
Publication of EA003476B1 publication Critical patent/EA003476B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

В изобретении предложены порошковые композиции и способы доставки действующего вещества в легкие пациента. Состав действующего вещества в виде сухого порошка имеет как низкую сорбцию влаги, так и стойкость к гигроскопическому росту, в особенности при имитации условий в легких пациента.Международная заявка была опубликована вместе с отчетом о международном поиске.The invention provides powder compositions and methods for delivering the active substance to the patient’s lungs. The composition of the active substance in the form of a dry powder has both low moisture sorption and resistance to hygroscopic growth, especially when simulating conditions in the patient's lungs. The international application was published along with an international search report.

EA200100300A 1998-09-14 1999-09-13 Dry powder active agent pulmonary delivery EA003476B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10016398P 1998-09-14 1998-09-14
PCT/US1999/021109 WO2000015262A1 (en) 1998-09-14 1999-09-13 Dry powder active agent pulmonary delivery

Publications (2)

Publication Number Publication Date
EA200100300A1 true EA200100300A1 (en) 2001-10-22
EA003476B1 EA003476B1 (en) 2003-06-26

Family

ID=22278404

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100300A EA003476B1 (en) 1998-09-14 1999-09-13 Dry powder active agent pulmonary delivery

Country Status (44)

Country Link
EP (1) EP1117442A1 (en)
JP (1) JP2002524535A (en)
KR (1) KR20010075063A (en)
CN (1) CN1317977A (en)
AP (1) AP1374A (en)
AR (1) AR022090A1 (en)
AU (1) AU753014B2 (en)
BG (1) BG105430A (en)
BR (1) BR9913722A (en)
CA (1) CA2343920A1 (en)
CO (1) CO5130023A1 (en)
CZ (1) CZ2001829A3 (en)
DZ (1) DZ2892A1 (en)
EA (1) EA003476B1 (en)
EE (1) EE200100151A (en)
GE (1) GEP20043257B (en)
GT (1) GT199900156A (en)
HK (1) HK1042231A1 (en)
HN (1) HN1999000159A (en)
HR (1) HRP20010189A2 (en)
HU (1) HUP0103837A3 (en)
ID (1) ID28845A (en)
IL (2) IL141562A0 (en)
IS (1) IS5878A (en)
LT (1) LT4897B (en)
LV (1) LV12658B (en)
MA (1) MA25590A1 (en)
MY (1) MY129282A (en)
NO (1) NO20011251L (en)
NZ (1) NZ510168A (en)
OA (1) OA11781A (en)
PA (1) PA8481901A1 (en)
PE (1) PE20001061A1 (en)
PL (1) PL195574B1 (en)
SA (1) SA99200718B1 (en)
SK (1) SK3442001A3 (en)
TN (1) TNSN99173A1 (en)
TR (1) TR200101182T2 (en)
TW (1) TWI226248B (en)
UA (1) UA76085C2 (en)
UY (1) UY25711A1 (en)
WO (1) WO2000015262A1 (en)
YU (1) YU24201A (en)
ZA (1) ZA200101995B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4874483B2 (en) 1999-06-09 2012-02-15 ロバート イー． シーバース Supercritical fluid assisted nebulization and bubble drying
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
JP2005503425A (en) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション Delivery of drug ester by the prescribed inhalation route
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
NZ535323A (en) 2002-02-25 2008-02-29 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
AU2003232081B2 (en) * 2002-07-03 2009-02-05 Brandeis University Central airway administration for systemic delivery of therapeutics
JP2006513238A (en) * 2002-12-19 2006-04-20 ファルマシア・コーポレーション Non-hygroscopic formulations containing hygroscopic drugs
DE10338403A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
CN101098678A (en) 2004-04-23 2008-01-02 锡德克斯公司 Dpi formulation containing sulfoalkyl ether cyclodextrin
EP2540696B1 (en) 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans carotenoids, formulation and uses
RU2007137121A (en) * 2005-03-09 2009-04-20 Оно Фармасьютикал Ко., Лтд. (Jp) PARTICLE AND PREPARATION CONTAINING THE SPECIFIED PARTICLE
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
EP2581078B1 (en) 2005-10-26 2014-12-10 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20080035143A1 (en) * 2006-08-14 2008-02-14 Sievers Robert E Human-powered dry powder inhaler and dry powder inhaler compositions
US20100093875A1 (en) * 2006-10-25 2010-04-15 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation prevented from caking
EP1925295A1 (en) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stable powder formulation containing a new antichinolinergic agent
MX2009010988A (en) 2007-04-13 2010-03-15 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease.
JP2011502125A (en) 2007-10-31 2011-01-20 ディフュージョン・ファーマシューティカルズ・エルエルシー A new class of treatments that promote small molecule diffusion
ES2661215T3 (en) 2009-05-20 2018-03-28 Aeras Viral compositions; immunogens; spray dried; stable
CA2765697C (en) 2009-06-22 2019-11-12 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
IN2014MN02359A (en) * 2012-05-03 2015-08-14 Janssen R & D Ireland
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US20180043585A9 (en) * 2013-09-20 2018-02-15 Virginia Commonwealth University Delivery of particles using hygroscopic excipients
MX2017005692A (en) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Powder formulation.
CN115089569A (en) 2016-03-24 2022-09-23 扩散药品有限公司 Use of bipolar trans carotenoids in conjunction with chemotherapy and radiation therapy for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
EP0611567B1 (en) * 1992-06-12 2002-08-28 Teijin Limited Ultrafine powder for inhalation and production thereof
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
PT954282E (en) * 1997-01-16 2005-06-30 Massachusetts Inst Technology PREPARATION OF PARTICLES FOR INHALATION
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant

Also Published As

Publication number Publication date
BG105430A (en) 2001-12-29
NZ510168A (en) 2003-09-26
AU6039799A (en) 2000-04-03
NO20011251D0 (en) 2001-03-13
LT2001021A (en) 2001-11-26
TNSN99173A1 (en) 2005-11-10
CO5130023A1 (en) 2002-02-27
PA8481901A1 (en) 2002-04-25
PE20001061A1 (en) 2000-10-08
WO2000015262A1 (en) 2000-03-23
TR200101182T2 (en) 2001-09-21
GT199900156A (en) 2001-03-07
HK1042231A1 (en) 2002-08-09
CA2343920A1 (en) 2000-03-23
SA99200718B1 (en) 2006-11-04
LT4897B (en) 2002-02-25
IL141562A0 (en) 2002-03-10
AP2001002093A0 (en) 2001-03-31
EA003476B1 (en) 2003-06-26
MY129282A (en) 2007-03-30
HRP20010189A2 (en) 2005-04-30
NO20011251L (en) 2001-04-17
DZ2892A1 (en) 2003-12-15
IL141562A (en) 2007-07-24
BR9913722A (en) 2001-05-29
CN1317977A (en) 2001-10-17
PL195574B1 (en) 2007-10-31
PL346768A1 (en) 2002-02-25
ZA200101995B (en) 2002-03-11
OA11781A (en) 2005-07-26
HUP0103837A3 (en) 2002-11-28
LV12658B (en) 2001-09-20
UY25711A1 (en) 1999-11-17
YU24201A (en) 2003-08-29
AU753014B2 (en) 2002-10-03
HUP0103837A2 (en) 2002-05-29
GEP20043257B (en) 2004-06-25
MA25590A1 (en) 2002-12-31
KR20010075063A (en) 2001-08-09
HN1999000159A (en) 1999-11-11
AP1374A (en) 2005-02-28
IS5878A (en) 2001-03-05
TWI226248B (en) 2005-01-11
JP2002524535A (en) 2002-08-06
AR022090A1 (en) 2002-09-04
UA76085C2 (en) 2006-07-17
ID28845A (en) 2001-07-05
EP1117442A1 (en) 2001-07-25
EE200100151A (en) 2002-06-17
LV12658A (en) 2001-05-20
SK3442001A3 (en) 2001-11-06
CZ2001829A3 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
EA200100300A1 (en) DRY POWDER CONTAINING EXISTING SUBSTANCE, AND METHOD OF DELIVERY TO LIGHT PATIENT OF EXISTING SUBSTANCE
EA200200431A1 (en) PHARMACEUTICAL COMPOSITIONS PROVIDING IMPROVED MEDICAL CONCENTRATIONS
EA200301275A1 (en) CAPSULES FOR INHALATION
SE8902377D0 (en) PROCEDURE FOR THE PREPARATION OF A WEAVEN BINDING AGENT
DE60121027D1 (en) SOLUTION FOR EVALUATION AND PRESERVATION
ATE362314T1 (en) HERBICIDE COMPOSITIONS COMPRISING IMIDAZOLINONE ACID
BR9705484A (en) Flavored zinc compositions for oral use incorporating copper
SE8300598L (en) STABILIZED INSULIN SOLUTIONS AND PROCEDURES FOR THEIR PREPARATION
EA199900194A1 (en) Removable Composition
CY1105528T1 (en) LONG-TERM STABILIZED PREPARATIONS
SE8000470L (en) TISSUE BINDING AND PROCEDURE FOR ITS MANUFACTURING AND USING THE BINDING AGENT
DE69840106D1 (en) FORMULATIONS FOR AMYLIN PEPTIDAGONISTS WITH INSULIN
CY1112139T1 (en) A PHARMACEUTICAL COMPOSITION INCLUDING CRYSTALL RITONAVIR FORM II AND A PREPARATION THEREOF
EA200300503A1 (en) NEW MEDICINAL COMPOSITIONS BASED ON SALTS OF TIOTROPY AND SALTS OF SALMETEROL
EA200500388A1 (en) METHOD OF OBTAINING DRY POWDER COMPOSITIONS FOR INHALATION
LV10181A (en) The content of nicotine content stimulates
IT1247945B (en) AGENT HAVING BACTERIOSTATIC AND BACTERICIDAL ACTIVITY
EA200100354A1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING ENTACAPON OR NITEKAPON, AND ALSO TRANSFORMED LINKED DERIVATIVES OF CELLULOSE
BR0109997A (en) Active substance combinations with insecticidal and acaricidal properties
ATE424192T1 (en) STABLE PHARMACEUTICAL PREPARATIONS CONTAINING 2-AZA-BICYCLO 3.3.0 -OCTANE-3-CARBOXYLIC ACID DERIVATIVES
ATE65401T1 (en) STABLE, INJECTABLE SOLUTIONS OF SALTS OF VINCRISTIN.
DE60103619D1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING ALGINATES
EP1136080A3 (en) Use of o-vanillin and o-vanillin/trolox combinations
PT769951E (en) LONG-TERM OXYTETRACYCLINE COMPOSITION
EA200100098A1 (en) SALT PAROXETINE

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM RU